Kyle Bass is the principal and founder of Hayman Capital Management, a hedge-capital firm based in Dallas. He came into the limelight when he made millions by predicting the 2008 mortgage crisis. For a period, people thought he was a super genius who could hardly make a mistake. In the year 2001, he got nominated for his direction and for writing the script for The Sixth Sense. He was undoubtedly gifted in the sense that he could make achievements in both the financial and entertainment worlds. However, as time passed, this perception started to change slowly in many people.
The magic touch he once possessed is surely gone for good. Synonymous to a movie maker who makes pathetic movies one after the other, he has been on a devastating trend of making bad calls one after the other. The most wrong thing with his is the fact that he has done that in the full glare of the public and media cameras. He has been hopping from one television station offering unprofessional analysis that instead of building his profile and reputation, does the complete opposite.
UsefulStooges said he has also found himself making the wrong choice of acquaintances. One such close friend is Cristina Fernández de Kirchner, an Argentinian, who is considered illiterate by many economists. When many people think that Cristina has made grave mistakes that have cost her country economically, he has been going round singing praises for her. His company has also been embroiled in some unprofessional activities that have not done it and himself any good. Instead of picking up his sleeves and trying to amend, Bass has been quick to rush into other unethical quick money making schemes.
He is the mastermind behind a scheme where he makes pharmaceutical companies suffer while he laughs all the way to the bank. The scheme involves picking up a company, short-selling its stock and then rushing to challenge one of its patents through the Coalition for Affordable Drugs, which he formed precisely for this sole purpose. For a man who made his money through suing anyone within reach, he does not care if this scheme makes patients who depend on the drugs whose patents he is challenging suffer provided he makes a buck.
To make matters worse, he has even blatantly admitted that the move is all about making money and not necessarily tailored for the welfare of the society. Government agencies have also been quick to challenge his move, and some are considering sanctioning him. Some pharmaceutical companies have also challenged the same move, and it is expected to drive his ‘professional’ career further down the pit. Only time will tell if he will have another chance to embarrass himself in an attempt to bring down others.